

# Pharmacy Benefact

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS

Number 770 • November 2018

## Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the December 1, 2018 Updates to the Alberta Drug Benefit List (ADBL) has been posted online at [www.ab.bluecross.ca/dbl/publications.html](http://www.ab.bluecross.ca/dbl/publications.html)

Please refer to the December 1, 2018 Updates for complete listings of products available by special authorization, added products, new established interchangeable groupings, least cost alternative price changes, products with a price change and discontinued listings.

Please note that the online *Interactive Drug Benefit List (iDBL)* at [www.ab.bluecross.ca/dbl/idbl\\_main1.html](http://www.ab.bluecross.ca/dbl/idbl_main1.html) is a near real-time application, and as such, contains the most up-to-date information.

### Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Altius Healthcare Inc. and Sanis Health Inc. that the shortage for Pantoprazole Magnesium 40 mg Enteric-Coated Tablet (DIN 02441853) and Pantoprazole T 40 mg Enteric-Coated Tablet (DIN 02466147) respectively has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **December 10, 2018**.

#### PANTOPRAZOLE MAGNESIUM

##### 40 MG ENTERIC-COATED TABLET

00002408570	MYLAN-PANTOPRAZOLE T	MYP	\$ 0.1875
00002441853	PANTOPRAZOLE MAGNESIUM	ALH	\$ 0.1875
00002466147	PANTOPRAZOLE T	SNS	\$ 0.1875
00002440628	TEVA-PANTOPRAZOLE MAGNESIUM	TEV	\$ 0.1875
00002267233	TECTA	TAK	\$ 0.7500

Alberta Blue Cross has been advised by Taro Pharmaceuticals Inc. that the shortage for Taro-Mometasone 0.1 % Topical Cream (DIN 02367157) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **December 20, 2018**.

#### MOMETASONE FUROATE

##### 0.1 % TOPICAL CREAM

00002367157	TARO-MOMETASONE	TAR	\$ 0.5708
00000851744	ELOCOM	MFC	\$ 0.7098

continued on next page ...

... continued from previous page

## Removal of temporary benefits from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Diphenhydramine HCl 50 mg/ml Injection (DIN 00596612) manufactured by Sandoz Canada Inc., Diphenhydramine Hydrochloride 50 mg/ml Injection (DIN 02369567) manufactured by Fresenius Kabi Canada and Diphenist 50 mg/ml Injection (DIN 02219336) manufactured by Omega Laboratories Limited were added as temporary benefits for the *Alberta Drug Benefit List (ADBL)*.

Sandoz Canada Inc. has advised Alberta Blue Cross that the shortage of Diphenhydramine HCl 50 mg/ml Injection (DIN 00596612) has been resolved.

As a result, Diphenhydramine Hydrochloride 50 mg/ml Injection (DIN 02369567) and Diphenist 50 mg/ml Injection (DIN 02219336) will no longer be considered temporary benefits for the *ADBL* after **December 12, 2018**.

---

Due to the shortages of Epipen 1:1000 Auto Injector Syringe (DIN 00509558) and Epipen Jr 1:2000 Auto Injector Syringe (DIN 00578657) manufactured by Mylan Specialty LP / Pfizer Canada Inc., Epinephrine 1 mg/ml Injection USP (DIN 00721891) manufactured by Hospira Healthcare Corporation was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Mylan Specialty LP / Pfizer Canada Inc. has advised Alberta Blue Cross that the shortages of Epipen 1:1000 Auto Injector Syringe (DIN 00509558) and Epipen Jr 1:2000 Auto Injector Syringe (DIN 00578657) have been resolved.

As a result, Epinephrine 1 mg/ml Injection USP (DIN 00721891) will no longer be considered a temporary benefit for the *ADBL* after **December 19, 2018**.

---

Due to the shortages of Epipen 1:1000 Auto Injector Syringe (DIN 00509558) and Epipen Jr 1:2000 Auto Injector Syringe (DIN 00578657) manufactured by Mylan Specialty LP / Pfizer Canada Inc., Auvi-Q 0.15 mg Auto-Injector Syringe (PIN 02480360) and Auvi-Q 0.3 mg Auto-Injector Syringe (PIN 02480379) manufactured by Kaleo Inc. were added as temporary benefits for the *Alberta Drug Benefit List (ADBL)*.

Mylan Specialty LP / Pfizer Canada Inc. has advised Alberta Blue Cross that the shortages of Epipen 1:1000 Auto Injector Syringe (DIN 00509558) and Epipen Jr 1:2000 Auto Injector Syringe (DIN 00578657) have been resolved.

As a result, Auvi-Q 0.15 mg Auto-Injector Syringe (PIN 02480360) and Auvi-Q 0.3 mg Auto-Injector Syringe (PIN 02480379) will no longer be considered temporary benefits for the *ADBL* after **December 19, 2018**.

---

### When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

**780-498-8370** (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)

**FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php)



\*\*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. \*† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.770 2018/11

